INTENSITY THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.023 USD | +6.99% |
|
+4.22% | -53.06% |
Valuation
| Fiscal Period: December | 2023 | 2024 |
|---|---|---|
| Capitalization 1 | 117.5 | 51.55 |
| Enterprise Value (EV) 1 | 117.5 | 51.55 |
| P/E ratio | -6.21 x | -4.09 x |
| Yield | - | - |
| Capitalization / Revenue | - | - |
| EV / Revenue | - | - |
| EV / EBITDA | - | - |
| EV / FCF | - | - |
| FCF Yield | - | - |
| Price to Book | - | - |
| Nbr of stocks (in thousands) | 13,709 | 13,709 |
| Reference price 2 | 8.570 | 3.760 |
| Announcement Date | 14/03/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net sales 1 | - | - | - |
| EBITDA | - | - | - |
| EBIT 1 | - | -8.319 | -10.1 |
| Operating Margin | - | - | - |
| Earnings before Tax (EBT) 1 | - | -10.54 | -9.35 |
| Net income 1 | -7.582 | -11.86 | -9.35 |
| Net margin | - | - | - |
| EPS 2 | -2.220 | -1.380 | -0.9200 |
| Free Cash Flow | - | - | - |
| FCF margin | - | - | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 18/05/23 | 14/03/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT | -1.222 | -2.491 | -3.353 | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | -3.701 | -2.33 | -3.171 | - | - | - | - |
| Net income | -3.701 | -2.33 | -4.495 | - | - | - | - |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -1.050 | -0.1700 | -0.1200 | -0.3400 | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 14/08/23 | 13/11/23 | 14/03/24 | 09/05/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Debt | - | - | - |
| Net Cash position | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - |
| Free Cash Flow | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - |
| Assets 1 | - | - | - |
| Book Value Per Share | - | - | - |
| Cash Flow per Share 2 | - | -0.8400 | -0.5300 |
| Capex | - | - | - |
| Capex / Sales | - | - | - |
| Announcement Date | 18/05/23 | 14/03/24 | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.76
USD
Average target price
12
USD
Spread / Average Target
+219.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -53.06% | 51.55M | |
| +18.12% | 47.02B | |
| +48.77% | 41.86B | |
| +0.57% | 41.76B | |
| -4.27% | 28.8B | |
| +11.98% | 26.05B | |
| -21.39% | 19.15B | |
| +4.47% | 12.55B | |
| +28.46% | 12.34B | |
| -4.48% | 11.82B |
- Stock Market
- Equities
- INTS Stock
- Financials Intensity Therapeutics, Inc.
